Cover Image
市場調查報告書

憂鬱症:開發中產品分析

Depression - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213106
出版日期 內容資訊 英文 494 Pages
訂單完成後即時交付
價格
Back to Top
憂鬱症:開發中產品分析 Depression - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 494 Pages
簡介

憂鬱症會引起心理障礙,持續性的悲傷和興趣喪失。一般常見的名稱有重度憂鬱症、重度憂鬱性障礙或是臨床憂鬱症。常見有睡眠障礙(失眠症,過眠症),食慾的變化,神經不安症,興奮或無法沉靜,身體問題(背部痛,頭痛)的徵兆和症狀。治療法包含抗憂鬱藥,心情穩定劑或抗精神病藥等。

本報告提供憂鬱症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

憂鬱症概要

治療藥的開發

憂鬱症:企業開發中的治療藥

憂鬱症:大學/機關研究中的治療藥

憂鬱症:開發中產品概況

憂鬱症:企業開發中的產品

憂鬱症:大學/機關研究中的產品

憂鬱症的治療藥的開發企業

憂鬱症:治療藥的評估

藥物簡介

憂鬱症:最近的開發平台趨勢

憂鬱症:暫停中的計劃

憂鬱症:開發中止的產品

憂鬱症:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8468IDB

Summary

Global Markets Direct's, 'Depression - Pipeline Review, H2 2016', provides an overview of the Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Depression
  • The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Depression therapeutics and enlists all their major and minor projects
  • The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Depression

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Depression
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Depression Overview
  • Therapeutics Development
  • Depression - Therapeutics under Development by Companies
  • Depression - Therapeutics under Investigation by Universities/Institutes
  • Depression - Pipeline Products Glance
  • Depression - Products under Development by Companies
  • Depression - Products under Investigation by Universities/Institutes
  • Depression - Companies Involved in Therapeutics Development
  • Depression - Therapeutics Assessment
  • Drug Profiles
  • Depression - Dormant Projects
  • Depression - Discontinued Products
  • Depression - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Depression, H2 2016
  • Number of Products under Development for Depression - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Depression - Pipeline by AB Science SA, H2 2016
  • Depression - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
  • Depression - Pipeline by Adamed Sp. z o.o., H2 2016
  • Depression - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Depression - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
  • Depression - Pipeline by Alkermes Plc, H2 2016
  • Depression - Pipeline by Allergan Plc, H2 2016
  • Depression - Pipeline by Alvogen Korea Co., Ltd., H2 2016
  • Depression - Pipeline by Amorsa Therapeutics Inc., H2 2016
  • Depression - Pipeline by Anavex Life Sciences Corp., H2 2016
  • Depression - Pipeline by Angelini Group, H2 2016
  • Depression - Pipeline by Angita B.V., H2 2016
  • Depression - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by AstraZeneca Plc, H2 2016
  • Depression - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by Axsome Therapeutics Inc, H2 2016
  • Depression - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by BioCrea GmbH, H2 2016
  • Depression - Pipeline by Biogen Inc, H2 2016
  • Depression - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016
  • Depression - Pipeline by BioLite, Inc., H2 2016
  • Depression - Pipeline by Bionomics Limited, H2 2016
  • Depression - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Depression - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Depression - Pipeline by Calico LLC, H2 2016
  • Depression - Pipeline by Celon Pharma Sp. z o.o., H2 2016
  • Depression - Pipeline by Cerecor Inc., H2 2016
  • Depression - Pipeline by Clera Inc., H2 2016
  • Depression - Pipeline by D-Pharm Ltd., H2 2016
  • Depression - Pipeline by Delpor, Inc., H2 2016
  • Depression - Pipeline by e-Therapeutics Plc, H2 2016
  • Depression - Pipeline by Eisai Co., Ltd., H2 2016
  • Depression - Pipeline by Eli Lilly and Company, H2 2016
  • Depression - Pipeline by Evotec AG, H2 2016
  • Depression - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Depression - Pipeline by GliaCure Inc., H2 2016
  • Depression - Pipeline by H. Lundbeck A/S, H2 2016
  • Depression - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Depression - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016
  • Depression - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Depression - Pipeline by Impel NeuroPharma, Inc., H2 2016
  • Depression - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Depression - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
  • Depression - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Depression - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by Johnson & Johnson, H2 2016
  • Depression - Pipeline by KemPharm, Inc., H2 2016
  • Depression - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Depression - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Depression - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016
  • Depression - Pipeline by Luye Pharma Group Ltd., H2 2016
  • Depression - Pipeline by Mapi Pharma Ltd., H2 2016
  • Depression - Pipeline by Mapreg S.A.S., H2 2016
  • Depression - Pipeline by Meta-IQ ApS, H2 2016
  • Depression - Pipeline by Methylation Sciences Inc., H2 2016
  • Depression - Pipeline by miCure Therapeutics Ltd., H2 2016
  • Depression - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Depression - Pipeline by Navya Biologicals Pvt Ltd, H2 2016
  • Depression - Pipeline by Neuralstem, Inc., H2 2016
  • Depression - Pipeline by Neurocrine Biosciences, Inc., H2 2016
  • Depression - Pipeline by NeuroNascent, Inc., H2 2016
  • Depression - Pipeline by NeurOp, Inc, H2 2016
  • Depression - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016
  • Depression - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016
  • Depression - Pipeline by nLife Therapeutics, S.L., H2 2016
  • Depression - Pipeline by Novartis AG, H2 2016
  • Depression - Pipeline by Omeros Corporation, H2 2016
  • Depression - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Depression - Pipeline by Pfizer Inc., H2 2016
  • Depression - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by Polleo Pharma Limited, H2 2016
  • Depression - Pipeline by Protagenic Therapeutics Inc., H2 2016
  • Depression - Pipeline by Relmada Therapeutics, Inc., H2 2016
  • Depression - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
  • Depression - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Depression - Pipeline by Saniona AB, H2 2016
  • Depression - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Depression - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Depression - Pipeline by Supernus Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by Suven Life Sciences Ltd., H2 2016
  • Depression - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016
  • Depression - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Depression - Pipeline by Tetra Discovery Partners LLC, H2 2016
  • Depression - Pipeline by Trevena, Inc., H2 2016
  • Depression - Pipeline by TRImaran Pharma, Inc., H2 2016
  • Depression - Pipeline by Turing Pharmaceuticals AG , H2 2016
  • Depression - Pipeline by VistaGen Therapeutics , Inc., H2 2016
  • Depression - Pipeline by Zhejiang Huahai Pharmaceutical Co., Ltd., H2 2016
  • Depression - Pipeline by Zogenix, Inc., H2 2016
  • Depression - Pipeline by Zysis Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Depression - Dormant Projects, H2 2016
  • Depression - Dormant Projects (Contd..1), H2 2016
  • Depression - Dormant Projects (Contd..2), H2 2016
  • Depression - Dormant Projects (Contd..3), H2 2016
  • Depression - Dormant Projects (Contd..4), H2 2016
  • Depression - Dormant Projects (Contd..5), H2 2016
  • Depression - Dormant Projects (Contd..6), H2 2016
  • Depression - Dormant Projects (Contd..7), H2 2016
  • Depression - Dormant Projects (Contd..8), H2 2016
  • Depression - Dormant Projects (Contd..9), H2 2016
  • Depression - Dormant Projects (Contd..10), H2 2016
  • Depression - Dormant Projects (Contd..11), H2 2016
  • Depression - Dormant Projects (Contd..12), H2 2016
  • Depression - Dormant Projects (Contd..13), H2 2016
  • Depression - Dormant Projects (Contd..14), H2 2016
  • Depression - Dormant Projects (Contd..15), H2 2016
  • Depression - Dormant Projects (Contd..16), H2 2016
  • Depression - Dormant Projects (Contd..17), H2 2016
  • Depression - Dormant Projects (Contd..18), H2 2016
  • Depression - Dormant Projects (Contd..19), H2 2016
  • Depression - Dormant Projects (Contd..20), H2 2016
  • Depression - Dormant Projects (Contd..21), H2 2016
  • Depression - Dormant Projects (Contd..22), H2 2016
  • Depression - Dormant Projects (Contd..23), H2 2016
  • Depression - Dormant Projects (Contd..24), H2 2016
  • Depression - Discontinued Products, H2 2016
  • Depression - Discontinued Products (Contd..1), H2 2016
  • Depression - Discontinued Products (Contd..2), H2 2016
  • Depression - Discontinued Products (Contd..3), H2 2016
  • Depression - Discontinued Products (Contd..4), H2 2016
  • Depression - Discontinued Products (Contd..5), H2 2016
  • Depression - Discontinued Products (Contd..6), H2 2016
  • Depression - Discontinued Products (Contd..7), H2 2016

List of Figures

  • Number of Products under Development for Depression, H2 2016
  • Number of Products under Development for Depression - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top